Developer docs
API playgroundTry for free, no card

Search company profiles

Meda

Full company profile

uuid0009p5p

Namestring
Meda
Legal namestring
Meda
Websiteurl
meda.se
Company typeenum
Private
Founded yearint
1954
Descriptiontext

meda is a recently launched German startup, headquartered in Munich, that builds AI-powered documentation and billing software for doctors and medical practices. The product integrates two workflows into a single platform: (1) automated clinical documentation, using natural language processing to generate and manage patient records, clinical notes, and medical forms from doctor input; and (2) automated billing, handling claims submission, payment processing, and revenue cycle management for medical practices. The two AI modalities disclosed are text (patient records, clinical notes, forms) and structured data (claims, invoices, financial records). The target customer segment is horizontal: individual doctors and medical practices that face administrative burden from documentation and billing complexity. Pricing is not publicly disclosed, no specific distribution or marketing channels are documented, and the company currently operates only in Germany within Western Europe. No funding rounds, headcount, revenue figures, customer logos, or management team information are disclosed in available sources, indicating an early pre-revenue or pre-traction stage as of the March 2026 reference date.

Note on data conflict: the firmographics block in the input also references "Meda AB," a Solna, Sweden-headquartered specialty pharmaceutical company founded in 1954 with 5,001–10,000 employees, including historical acquisitions of Rottapharm (2014), Acton Pharmaceuticals (2013), and Viatris (2005). These attributes describe a distinct, long-established pharma entity (which itself was later absorbed into Mylan/Viatris) and are not consistent with the operational data — AI documentation software, Munich headquarters, recent launch — that constitutes the bulk of the structured evidence. The analytical outputs above are grounded in the AI-startup operational data, which is more specific and more recent.

Short descriptiontext

meda is a Munich-based German startup providing AI-powered clinical documentation and medical billing software for doctors and medical practices, automating patient notes, claims, and revenue cycle workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, branded medicines, prescription drugs, pharmaceutical products, therapeutic treatments
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Cost components5 values
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Meda is an international specialty pharmaceutical company that develops, manufactures, and markets branded prescription pharmaceutical products across multiple therapeutic areas. Headquartered in Solna, Sweden since its 1954 founding, the company has expanded its portfolio and geographic footprint through strategic acquisitions including Rottapharm in 2014, Acton Pharmaceuticals in 2013, and Viatris in 2005.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

meda provides AI documentation and billing software designed specifically for doctors. The company's core product is an integrated AI-powered solution that combines automated medical documentation with billing software functionality, helping healthcare practitioners streamline their administrative workflows.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Shire (Takeda)
TypeBroad incumbent
Description

Ireland-headquartered specialty pharmaceutical company (now part of Takeda) historically focused on rare diseases, neuroscience, and internal medicine. Comparable to Meda AB as a specialty pharma of similar acquisition-driven growth profile that ultimately consolidated into a larger player.

2Jazz Pharmaceuticals
TypeDirect peer
Description

Ireland-based specialty pharmaceutical company focused on CNS and oncology. Comparable to Meda AB in specialty pharma positioning, European corporate domicile, and acquisition-driven growth strategy.

3Endo International
TypeDirect peer
Description

Irish-domiciled specialty pharmaceutical company with franchises in branded specialty, generics, and sterile injectables. Comparable to Meda AB as a specialty pharma with overlapping product categories and similar size profile.

4Almirall
TypeDirect peer
Description

Spanish specialty pharmaceutical company focused on dermatology and specialty care across Europe. Closely comparable to Meda AB as a mid-cap European specialty pharma with overlapping therapeutic areas and similar commercial channels.

5H. Lundbeck
TypeDirect peer
Description

Danish specialty pharmaceutical company focused on brain diseases (CNS). Comparable to Meda AB as a Nordic-headquartered specialty pharma with similar scale and European geographic concentration.

6UCB
TypeDirect peer
Description

Belgian specialty pharmaceutical company focused on neurology and immunology. Comparable to Meda AB as a mid-cap European specialty pharma with similar product mix and distribution model.

7Viatris
TypeBroad incumbent
Description

Global healthcare company formed through the merger of Mylan and Upjohn, and now the parent entity of Meda AB. Comparable as the broader incumbent that absorbed Meda's specialty portfolio, providing scale and global distribution that Meda operated within.

8Ferring Pharmaceuticals
TypeDirect peer
Description

Swiss privately-held specialty pharmaceutical company with focus on reproductive health, gastroenterology, and urology. Comparable to Meda AB as a European privately-held specialty pharma of similar scale.

9Ipsen
TypeDirect peer
Description

French specialty pharmaceutical company with strong positions in oncology, neurology, and rare diseases. Comparable to Meda AB as a European-headquartered specialty pharma of similar scale.

10Recordati
TypeDirect peer
Description

Italian specialty pharmaceutical company operating across Europe with a focus on rare diseases and specialty care. Comparable to Meda AB in size, European geographic focus, and specialty pharma positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Meda

Specialty Pharmaceuticalsmeda.se

meda is a Munich-based German startup providing AI-powered clinical documentation and medical billing software for doctors and medical practices, automating patient notes, claims, and revenue cycle workflows.

What Meda does

meda is a recently launched German startup, headquartered in Munich, that builds AI-powered documentation and billing software for doctors and medical practices. The product integrates two workflows into a single platform: (1) automated clinical documentation, using natural language processing to generate and manage patient records, clinical notes, and medical forms from doctor input; and (2) automated billing, handling claims submission, payment processing, and revenue cycle management for medical practices. The two AI modalities disclosed are text (patient records, clinical notes, forms) and structured data (claims, invoices, financial records). The target customer segment is horizontal: individual doctors and medical practices that face administrative burden from documentation and billing complexity. Pricing is not publicly disclosed, no specific distribution or marketing channels are documented, and the company currently operates only in Germany within Western Europe. No funding rounds, headcount, revenue figures, customer logos, or management team information are disclosed in available sources, indicating an early pre-revenue or pre-traction stage as of the March 2026 reference date.

Note on data conflict: the firmographics block in the input also references "Meda AB," a Solna, Sweden-headquartered specialty pharmaceutical company founded in 1954 with 5,001–10,000 employees, including historical acquisitions of Rottapharm (2014), Acton Pharmaceuticals (2013), and Viatris (2005). These attributes describe a distinct, long-established pharma entity (which itself was later absorbed into Mylan/Viatris) and are not consistent with the operational data — AI documentation software, Munich headquarters, recent launch — that constitutes the bulk of the structured evidence. The analytical outputs above are grounded in the AI-startup operational data, which is more specific and more recent.

Meda firmographics

Firmographics
Name
Meda
Legal name
Meda
Website
https://meda.se
Company type
Private
Founded year
1954
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
meda is a Munich-based German startup providing AI-powered clinical documentation and medical billing software for doctors and medical practices, automating patient notes, claims, and revenue cycle workflows.
Ownership category
akta.pro rank

Where Meda is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Meda business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Meda product offering

Product offering

Core offering

Meda is an international specialty pharmaceutical company that develops, manufactures, and markets branded prescription pharmaceutical products across multiple therapeutic areas. Headquartered in Solna, Sweden since its 1954 founding, the company has expanded its portfolio and geographic footprint through strategic acquisitions including Rottapharm in 2014, Acton Pharmaceuticals in 2013, and Viatris in 2005.

Product overview

meda provides AI documentation and billing software designed specifically for doctors. The company's core product is an integrated AI-powered solution that combines automated medical documentation with billing software functionality, helping healthcare practitioners streamline their administrative workflows.

Differentiator

Problem solved

Functional benefit

Companies that use Meda

Customer profile

Segments1 record

Ideal customer profiles1 record

Meda technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Meda partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights2 records

Meda competitors and assessment

Company assessment

Broad incumbents

  • Shire (Takeda): Ireland-headquartered specialty pharmaceutical company (now part of Takeda) historically focused on rare diseases, neuroscience, and internal medicine. Comparable to Meda AB as a specialty pharma of similar acquisition-driven growth profile that ultimately consolidated into a larger player.
  • Viatris: Global healthcare company formed through the merger of Mylan and Upjohn, and now the parent entity of Meda AB. Comparable as the broader incumbent that absorbed Meda's specialty portfolio, providing scale and global distribution that Meda operated within.

Direct peers

  • Jazz Pharmaceuticals: Ireland-based specialty pharmaceutical company focused on CNS and oncology. Comparable to Meda AB in specialty pharma positioning, European corporate domicile, and acquisition-driven growth strategy.
  • Endo International: Irish-domiciled specialty pharmaceutical company with franchises in branded specialty, generics, and sterile injectables. Comparable to Meda AB as a specialty pharma with overlapping product categories and similar size profile.
  • Almirall: Spanish specialty pharmaceutical company focused on dermatology and specialty care across Europe. Closely comparable to Meda AB as a mid-cap European specialty pharma with overlapping therapeutic areas and similar commercial channels.
  • H. Lundbeck: Danish specialty pharmaceutical company focused on brain diseases (CNS). Comparable to Meda AB as a Nordic-headquartered specialty pharma with similar scale and European geographic concentration.
  • UCB: Belgian specialty pharmaceutical company focused on neurology and immunology. Comparable to Meda AB as a mid-cap European specialty pharma with similar product mix and distribution model.
  • Ferring Pharmaceuticals: Swiss privately-held specialty pharmaceutical company with focus on reproductive health, gastroenterology, and urology. Comparable to Meda AB as a European privately-held specialty pharma of similar scale.
  • Ipsen: French specialty pharmaceutical company with strong positions in oncology, neurology, and rare diseases. Comparable to Meda AB as a European-headquartered specialty pharma of similar scale.
  • Recordati: Italian specialty pharmaceutical company operating across Europe with a focus on rare diseases and specialty care. Comparable to Meda AB in size, European geographic focus, and specialty pharma positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Meda social profiles

Digital presence

Meda financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Meda leadership team

Management profile

Number of profiles

Profiles1 record

Meda funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Meda M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meda

What does Meda do?

Meda is an international specialty pharmaceutical company that develops, manufactures, and markets branded prescription pharmaceutical products across multiple therapeutic areas. Headquartered in Solna, Sweden since its 1954 founding, the company has expanded its portfolio and geographic footprint through strategic acquisitions including Rottapharm in 2014, Acton Pharmaceuticals in 2013, and Viatris in 2005.

Is Meda a public or private company?

Meda is a private company. It is classified as unknown and is currently operating.

When was Meda founded?

Meda was founded in 1954. It employs 5,001 to 10,000 people.

Where is Meda based?

Meda is headquartered in Solna, Sweden, in the Europe region.

Who are Meda's main competitors?

Broad incumbents on record are Shire (Takeda) and Viatris. Direct peers are Jazz Pharmaceuticals, Endo International, Almirall, H. Lundbeck, UCB, Ferring Pharmaceuticals, Ipsen and Recordati.

Does Meda have an API?

No public API is recorded for Meda.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ITRDecoding intellectual property ownership: insights from Swedish transfer pricing case lawA Swedish court ruled on April 10, 2024 in case 6754 that Meda AB, rather than its Luxembourg subsidiary LuxCo, was the true economic owner of pharmaceutical IP rights acquired during 2011–12, despite LuxCo holding formal legal ownership. The court determined that actual decision-making authority, risk control, and board oversight resided with Meda AB based on board meeting minutes and CEO involvement, ordering that residual profits be reallocated with 40% to other contributing group companies and routine compensation to LuxCo for administrative services. The ruling, along with prior Swedish cases involving bioMérieux, Datawatch, and Twilio, underscores the need for multinational enterprise groups to align contractual arrangements with actual operational conduct and decision-making to ensure compliant transfer pricing.PR NewswireMylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 GuidanceMylan N.V. reported full-year 2017 total revenues of $11.91 billion, an 8% increase driven by acquisitions such as Meda AB and strong performance in Europe and Rest of World segments. The company also announced a 2018 revenue guidance range of $11.75 billion to $13.25 billion and adjusted EPS expectations of $5.20 to $5.60, while acknowledging significant EpiPen sales declines in North America due to pricing pressures and legal settlements.PR NewswireMylan Reports Second Quarter 2017 Results and Updates 2017 GuidanceMylan N.V. announced Q2 2017 financial results with total revenues of $2.96 billion, up 16% year-over-year, driven by strong growth in Europe (+59%) and Rest of World (+29%) segments, partially offset by a 9% decline in North America. The company revised its 2017 full-year guidance downward, expecting total revenues of $11.5-$12.5 billion and adjusted EPS of $4.30-$4.70, citing delays in major U.S. launches including generic Advair and generic Copaxone to 2018 due to uncertain regulatory conditions. Net sales from the acquisitions of Meda and the Topicals Business contributed approximately $633 million, helping offset pricing pressures and increased EpiPen competition in North America.PR NewswireInformation to the Holders of Notes Issued by MedaMeda AB, which had previously issued SEK 600 million and SEK 750 million floating rate notes traded on Nasdaq Stockholm, has become a Mylan subsidiary following the completion of Mylan's public tender offer in August 2016. Mylan N.V. has issued a guarantee covering Meda's obligations to note holders, including interest payments and principal repayment on the respective maturity dates. In connection with this guarantee, Nasdaq Stockholm granted Meda an exemption from its financial statement publication requirements, with Mylan instead undertaking to publish its US GAAP financial reports in Sweden.GlobeNewswireBulletin from the extraordinary general meeting in Meda AB (publ)Meda AB's extraordinary general meeting on 25 August 2016 resolved that the board consist of Caroline Dixon, Jacek Glinka, and Colleen Ostrowski until the next annual general meeting, with Jacek Glinka as chairman. The company is a specialty pharma firm with products sold in over 150 countries.PR NewswireMylan slutför förvärvet av MedaMylan N.V. has completed the acquisition of Meda Aktiebolag by paying consideration to shareholders who accepted the tender offer for approximately 94 percent of outstanding shares. This transaction results in Mylan gaining significant expansion in its product portfolio, geographic reach, and commercial infrastructure across developed and growth markets. The company now controls Meda as a subsidiary and intends to delist its shares from Nasdaq Stockholm.GlobeNewswireMeda Aktiebolag (publ) applies for delisting and convenes an extraordinary general meetingMylan N.V. declared its public offer for Meda Aktiebolag unconditional on August 2, 2016, and controls over 90% of shares. Meda's board convened an extraordinary general meeting on August 25, 2016, and applied for delisting from Nasdaq Stockholm. The last trading day will be announced after Nasdaq confirmation.GlobeNewswireExtraordinary General Meeting of Meda Aktiebolag (publ)Mylan N.V., holding over 90% of Meda's shares, requested an extraordinary general meeting on August 25, 2016. The meeting proposes a three-member board with no remuneration, and elects Caroline Dixon, Jacek Glinka, and Colleen Ostrowski, with Glinka as chairman.PR NewswireMylan Receives U.S. FTC Clearance for Proposed Meda AcquisitionMylan N.V. received final regulatory clearance from the U.S. Federal Trade Commission to acquire Meda Aktiebolag, marking the last antitrust approval needed for the transaction. This clearance removes the final conditional hurdle, allowing Mylan to proceed with its recommended public offer to tender all shares of Meda by July 29, 2016. The deal is subject to the divestiture of certain products not significant to Mylan's earnings.PR NewswireMylan påbegynder Meda-tilbud 17. juniMylan N.V. has received regulatory approval from the Swedish Financial Supervisory Authority for its recommended public offer to acquire Meda Aktiebolag. The official offer document was published on June 16, 2016, with the acceptance period running from June 17 to July 29, 2016. Settlement of the transaction is expected to begin around August 10, 2016.